VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, is slated to attend the upcoming Concordia Americas Summit. The 2022 Concordia Americas Summit is scheduled for July 13–14, 2022, in Miami as well as online. During the two-day summit, VistaGen CEO Shawn K. Singh will join U.S. Surgeon General Vice Admiral Vivek H. Murthy, MD, in a discussion about America’s ongoing mental health crisis. According to the announcement, the two will provide an overview of rising rates of anxiety and depression disorders and potential ways in which the COVID-19 pandemic has impacted the mental health landscape in the country. The discussion, which is slated for July 14 at 11:40 a.m. ET, will also include potential ways to improve access to treatment and diminish stigma around seeking care and resources. The 2022 America Summit, Concordia’s longest-standing regional initiative, gathers leaders from across industries, sectors and geographies to discuss the biggest challenges and opportunities facing the Western Hemisphere. “I am honored to join U.S. Surgeon General Murthy at this important moment in history when so many communities are seeking solutions to escalating mental health challenges,” said VistaGen CEO Shawn K. Singh in the press release. “VistaGen is helping lead the way by developing innovative therapies designed to change the trajectory of mental health care — one mind at a time.”

To view the event, visit https://ibn.fm/RTHwT

To view the full press release, visit https://ibn.fm/AdiN9

About VistaGen Therapeutics Inc.

VistaGen is a late clinical-stage, biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company is advancing therapeutics with the potential to be faster acting and with fewer side effects and safety concerns than those that are currently available. VistaGen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which are odorless neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen’s lead candidate, PH94B, is a nasally administered spray currently in multiple phase 3 trials in the United States, with top-line results anticipated this year. Should ongoing phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. For more information about the company, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.